New diagnostic tools and biomarker identification promise earlier and more accurate cancer detection. Owlstone Medical secured up to $49.1 million from ARPA-H to develop accessible, over-the-counter cancer screening tests detecting over 30 cancers at early stages. CareDx achieved IVDR certification for transplant compatibility assays enhancing HLA typing precision. AI-integrated transformer models use habitat analysis of PET imaging to predict cervical cancer prognosis, combining radiomic and dosimetric data for clinical guidance. These advances facilitate personalized oncology, improved treatment stratification, and broadened patient access to minimally invasive diagnostics.